Novel PET imaging technique may observe and information remedy for kind 1 diabetes (News)

0
18

IMAGE

IMAGE: TOP: Consultant axial slices of PET/CT overlay of pancreas uptake (white arrows) for every dopaminergic radioligand A) 11C-(+)-PHNO B) 11C-FLB457 and C) 11C-raclopride. All SUV photographs summed from 20-30 minutes….
view extra 

Credit score: J Bini et al., Yale College, New Haven, CT.

RESTON, VA – Researchers have found a brand new nuclear medication check that might enhance care of sufferers with kind 1 diabetes. The brand new positron emission tomography (PET) imaging technique may measure beta-cell mass, which might tremendously improve the flexibility to observe and information diabetes therapies. This examine is reported within the featured article of the month in The Journal of Nuclear Drugs‘s August problem.

In response to the American Diabetes Affiliation, roughly 1.25 million American youngsters and adults have kind 1 diabetes. Jason Bini, PhD, on the Yale College PET Middle in New Haven, Connecticut, explains the importance to sufferers of with the ability to observe their beta-cell mass:

    “Beta-cell mass consists of each purposeful and non-functional beta cells. Many oblique strategies to measure beta-cell perform are influenced by components comparable to glucose and insulin ranges and are usually not in a position to measure non-functional (dormant) beta cells which may be attentive to therapies. This work is essential for sufferers as a result of uptake of a radiotracer measured on a PET scan may information therapy choices. For instance, if a affected person has low beta-cell perform with excessive sign within the PET scan, this might signify a affected person with dormant beta cells that might reply to a therapy focusing on present cells. If a affected person has low beta-cell perform and low sign within the PET scan (only a few viable or dormant beta cells current), that particular person could also be a candidate for beta-cell transplantation.”

Beta cells and neurological tissues have frequent mobile receptors and transporters, so, the Yale researchers screened mind radioligands for his or her capacity to establish beta cells. Then, 12 wholesome management topics and two topics with kind 1 diabetes mellitus underwent dynamic PET/CT scans with six tracers.

The dopamine kind 2/kind 3 (D2/D3)-receptor agonist radioligand carbon-11 (11C)-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) was the one radioligand to exhibit sustained uptake within the pancreas with excessive distinction versus stomach organs such because the kidneys, liver, and spleen.

The outcomes present preliminary proof that 11C-(+)-PHNO is a possible marker of beta-cell mass with 2:1 binding of D3 receptors over D2 receptors. Whereas additional analysis is required earlier than medical utility, 11C-(+)-PHNO is a promising technique to differentiate the beta-cell mass of wholesome people from these with kind 1 diabetes mellitus, in addition to observe and information therapies for diabetes sufferers.

Bini additionally factors out, “These findings may facilitate improvement and wider dissemination of novel imaging strategies in molecular imaging and nuclear medication to evaluate receptor/enzyme pharmacology in diabetes and different endocrine problems.”

###

Authors of “Analysis of PET Mind Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO” embrace Jason Bini, Mika Naganawa, Nabeel Nabulsi, Yiyun Huang, Jim Ropchan, Keunpoong Lim, Soheila Najafzadeh, Kevan C. Herold, Gary W. Cline, and Richard E. Carson, Yale College, New Haven, Connecticut.

This examine was supported by Nationwide Institutes of Well being (NIH) grant 1DP3DK104092-01 and was additionally made doable by NIH grant 1S10OD010322-01 and by Scientific and Translational Science Awards (CTSA) grant UL1 TR000142 from the Nationwide Middle for Advancing Translational Sciences (NCATS) at NIH.

Please go to the SNMMI Media Middle to view the PDF of the examine, together with photographs, and extra details about molecular imaging and customized medication. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or [email protected] Present and previous problems with The Journal of Nuclear Drugs will be discovered on-line at http://jnm.snmjournals.org.

ABOUT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The Society of Nuclear Drugs and Molecular Imaging (SNMMI) is a global scientific and medical group devoted to advancing nuclear medication and molecular imaging, important components of precision medication that permit analysis and therapy to be tailor-made to particular person sufferers to be able to obtain the absolute best outcomes.

SNMMI’s greater than 17,000 members set the usual for molecular imaging and nuclear medication follow by creating pointers, sharing info via journals and conferences and main advocacy on key points that have an effect on molecular imaging and remedy analysis and follow. For extra info, go to http://www.snmmi.org.

Disclaimer: AAAS and EurekAlert! are usually not liable for the accuracy of News releases posted to EurekAlert! by contributing establishments or for using any info via the EurekAlert system.

READ  Experimental drug stops Parkinson's illness development in mice (News)

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.